✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Mavoglurant is an investigational drug.
There have been 6 clinical trials for Mavoglurant. The most recent clinical trial was a Phase 2 trial, which was initiated on August 17th 2017.
The most common disease conditions in clinical trials are Alcoholism, Cocaine-Related Disorders, and Syndrome. The leading clinical trial sponsors are Yale University, Novartis Pharmaceuticals, and Elizabeth Berry-Kravis.
There are fifty-five US patents protecting this investigational drug and five hundred and eighty-five international patents.
Recent Clinical Trials for Mavoglurant
|Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant||Yale University||Early Phase 1|
|Metabotropic Glutamate Receptor-5 (mGlur5) Effects on Reward-Related fMRI-BOLD Activation in FHP and FHN||Yale University||Early Phase 1|
|Mavoglurant in Alcohol Drinking||Yale University||Phase 1|
Top disease conditions for Mavoglurant
Top clinical trial sponsors for Mavoglurant
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Mavoglurant||See Plans and Pricing||Controlled release dosage form||TRIASTEK, INC. (Nanjing, CN)||See Plans and Pricing|
|Mavoglurant||See Plans and Pricing||Methods of treating sleep disorders||Melior Pharmaceuticals II, LLC (Exton, PA)||See Plans and Pricing|
|Mavoglurant||See Plans and Pricing||Composition and method for treating neurological disease||Osmotica Kereskedelmi es Szolgaltato Korlatolt Feleossegu Tarsasag (Budapest, HU)||See Plans and Pricing|
|Mavoglurant||See Plans and Pricing||Composition and method for treating neurological disease||Osmotica Kereskedelmi es Szolgaltato Korlatolt Felelossegu Tarsasag (Budapest, HU)||See Plans and Pricing|
|Mavoglurant||See Plans and Pricing||Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Mavoglurant||Australia||AU2017261372||2036-05-05||See Plans and Pricing|
|Mavoglurant||Canada||CA3023278||2036-05-05||See Plans and Pricing|
|Mavoglurant||China||CN107847398||2036-05-05||See Plans and Pricing|
|Mavoglurant||European Patent Office||EP3452003||2036-05-05||See Plans and Pricing|
|Mavoglurant||European Patent Office||EP3981392||2036-05-05||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|